Glas Annuska M, Floore Arno, Delahaye Leonie J M J, Witteveen Anke T, Pover Rob C F, Bakx Niels, Lahti-Domenici Jaana S T, Bruinsma Tako J, Warmoes Marc O, Bernards René, Wessels Lodewyk F A, Van't Veer Laura J
Agendia BV, Slotervaart Medical Center 9D, Louwesweg 6, 1066 EC Amsterdam, The Netherlands.
BMC Genomics. 2006 Oct 30;7:278. doi: 10.1186/1471-2164-7-278.
A 70-gene tumor expression profile was established as a powerful predictor of disease outcome in young breast cancer patients. This profile, however, was generated on microarrays containing 25,000 60-mer oligonucleotides that are not designed for processing of many samples on a routine basis.
To facilitate its use in a diagnostic setting, the 70-gene prognosis profile was translated into a customized microarray (MammaPrint) containing a reduced set of 1,900 probes suitable for high throughput processing. RNA of 162 patient samples from two previous studies was subjected to hybridization to this custom array to validate the prognostic value. Classification results obtained from the original analysis were then compared to those generated using the algorithms based on the custom microarray and showed an extremely high correlation of prognosis prediction between the original data and those generated using the custom mini-array (p < 0.0001).
In this report we demonstrate for the first time that microarray technology can be used as a reliable diagnostic tool. The data clearly demonstrate the reproducibility and robustness of the small custom-made microarray. The array is therefore an excellent tool to predict outcome of disease in breast cancer patients.
一种70基因肿瘤表达谱已被确立为年轻乳腺癌患者疾病预后的有力预测指标。然而，该表达谱是在包含25,000个60聚体寡核苷酸的微阵列上生成的，这些寡核苷酸并非为常规处理大量样本而设计。
为便于在诊断环境中使用，将70基因预后表达谱转化为定制微阵列（MammaPrint），该微阵列包含一组精简的1900个适合高通量处理的探针。来自两项先前研究的162例患者样本的RNA与该定制阵列进行杂交，以验证其预后价值。然后将原始分析获得的分类结果与使用基于定制微阵列的算法生成的结果进行比较，结果显示原始数据与使用定制微阵列生成的数据之间在预后预测方面具有极高的相关性（p < 0.0001）。
在本报告中，我们首次证明微阵列技术可作为一种可靠的诊断工具。数据清楚地证明了小型定制微阵列的可重复性和稳健性。因此，该阵列是预测乳腺癌患者疾病预后的极佳工具。
